Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. (Q45966674)

18 December 2017

title

Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. (English)

1 reference

18 December 2017

author name string

Scott T Tagawa

1 reference

18 December 2017

Eric Cheung

1 reference

18 December 2017

Warren Banta

1 reference

18 December 2017

Conway Gee

1 reference

18 December 2017

Jeffrey S Weber

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

18 December 2017

published in

Cancer

1 reference

18 December 2017

volume

106

1 reference

18 December 2017

issue

1 reference

18 December 2017

page(s)

1353-1357

1 reference

18 December 2017

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

The surgical management of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Lung metastases from melanoma: when is surgical treatment warranted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Metastasectomy for recurrent stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Surgical treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Diversity and recognition efficiency of T cell responses to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

7 January 2021

Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

7 January 2021

Surgical therapy for distant metastases of malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

7 January 2021

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

7 January 2021

Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

7 January 2021

Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21748

7 January 2021

Identifiers

DOI

10.1002/CNCR.21748

1 reference

18 December 2017

1 reference

18 December 2017